Synaptogenix Inc (SNPX)

[kld2]

antti, one more thing. I could be wrong and you could be right, 2 or 3 CU patients could demonstrate that there is efficacy. But let's then ask the Street what it thinks. Why is the MC at 145m for an indication that has potential sales of billions of dollars if the results of the Ph2b trial have a very good chance of being positive? Let's cut through the bs. It's the same with AVXL. There are a lot of smart investors with a hell out a lot of money who wouldn't touch either stock with a ten-foot pole. Just a fact. Look at the MC. Look at tute participation. Do you think we are the genius investors who have discovered the hidden gem? C'mon! Billions of dollars--that's why most people are in the stock market: to get rich, and if an opportunity presents itself, the Street will take it in a split second--or no? A cure for AD is staring them right in the eye and they fail to act? Think again. It is not a sure thing; it is less than a sure thing, and if anything reflects this uncertainty it is the MC--the potential value that the Street gives it. Those three CU mean squat to the Street. Dr. Akron's words mean squat to the Street. Likewise, Dr. Missling, the genius financier, means squat to the Street. If either of these two companies had the goods, the MC price would be at least 750m for a co. entering a Ph2/3 trial, and esp. for an indication like Alzheimer's.